Pre–Covid-19, SARS-CoV-2–Negative Multisystem Inflammatory Syndrome in Children
Sarah Benezech, Liliane Khoryati, Jade Cognard, Stejara A. Netea, Taushif Khan, Marion Moreews, Kahina Saker, Jean‐Marie De Guillebon, Samira Khaldi-Plassart, Rémi Pescarmona, Sébastien Viel, Christophe Malcus, Magali Perret, Meriadeg Ar Gouilh, Astrid Vabret, Fabienne Venet, Solenn Remy, Emilie Chopin, Gérard Lina, François Vandenesch, Noëmi Rousseaux, Paul Bastard, Shen‐Ying Zhang, Jean‐Laurent Casanova, Sophie Trouillet‐Assant, Thierry Walzer, Taco W. Kuijpers, Étienne Javouhey, Olivier Dauwalder, Nico Marr, Alexandre Bélot
Abstract
To The Editor:\nIn early 2020, multisystemic inflammatory syndrome in children (MIS-C) was recognized as an emerging life-threatening disease occurring 2 to 6 weeks after infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), with symptoms resembling those of Kawasaki’s disease or toxic shock syndrome.1 Unlike typical Kawasaki’s disease, MIS-C has been frequently associated with gastrointestinal symptoms and circulatory failure necessitating treatment with vasoactive drugs.